Buy4

Oncotelic Therapeutics, Inc.

OTLC

Total Value

$23.5K

Net $23.5K bought

Filing Date

Oct 30, 2026

2 transactions

Purchases

$23.5K

2 transactions

Trade Summary

On Oct 28, 2026, Trieu Vuong, CHAIRMAN AND CEO, Director, 10% Owner, purchased $23.5K of Oncotelic Therapeutics, Inc. (OTLC) across 2 transactions. The filing covers Common Stock and reflects net buying of $23.5K. Reported prices ranged from $0.02. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Trieu Vuong
Role: CHAIRMAN AND CEO, Director, 10% Owner
Location: AGOURA HILLS, CA

Filing Details

Filing Date: Oct 30, 2026
Transaction Date: Oct 28, 2026
Accession Number: 0001493152-26-049370
Form Type: 4
Net Trading Amount: $23.5K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
—	Common Stock	1,044,990	$0.02	Purchase	$17.8K
—	Common Stock	312,000	$0.02	Purchase	$5.8K

Want live alerts when Trieu Vuong trades again?

Download Insider Trades to track OTLC, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)On October 29, 2026, Dr. Vuong Trieu purchased 1,044,990 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.017.
(F2)On October 28, 2026, Dr. Vuong Trieu purchased 312,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0185.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trieu Vuong

(Last)

(First)

(Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS

91301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026⁽¹⁾	10/29/2026⁽¹⁾	P		1,044,990	A	$0.017	95,481,309	D
Common Stock	10/28/2026⁽²⁾	10/28/2026⁽²⁾	P		312,000	A	$0.0185	94,436,319	D
Common Stock								16,780,384	I	By Autotelic Inc.
Common Stock								6,872,529	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On October 29, 2026, Dr. Vuong Trieu purchased 1,044,990 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.017.

2. On October 28, 2026, Dr. Vuong Trieu purchased 312,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0185.

	/s/ Vuong Trieu	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001493152-26-049370.

Oncotelic Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when Trieu Vuong trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4